To read the full article sign up for free or sign in.

Hummingbird migrates ADCs, tech to newco Callio’s $187M debut

March 4, 2025

Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug technology and assets in-licensed from Hummingbird Bioscience Pte Ltd.

BioWorld BioWorld Asia Financings Newco news Cancer Immune Inflammatory Antibody-drug conjugate Monoclonal antibody Series A Asia-Pacific U.S.

Today's news in brief

BioWorld

BioWorld briefs for April 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 16, 2025.

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

Capsules and tablets scattered over a world map

Biopharma tariffs becoming more than a threat

BioWorld

U.S. tariffs on biopharmaceuticals have advanced beyond administration talking points.As a precursor to tariffs, Commerce Secretary Howard Lutnick initiated an...

Spruce acquires Biomarin’s Sanfilippo drug, tralesinidase alfa

BioWorld

After dropping development in December of its lead program, Spruce Biosciences Inc. has found new life by acquiring a BLA-ready enzyme replacement therapy for the...